地尔硫缓释剂与维拉帕米对轻中度原发性高血压患者随机、单盲、平行对照研究

目的:比较地尔硫缓释剂(Dilacor)与缓释维拉帕米治疗轻中度原发性高血压患者的降压效果及安全性。方法:共入选49例轻中度高血压患者并随机分为两组,A组:维拉帕米组共24例,每日服用240mg;B组:地尔硫(艹卓)组共25例,每日服用180mg或240mg。结果:服用180mg或240mg Dilacor8周可使84％患者平均收缩压下降9.92mmHg,平均舒张压下降10.48mmHg;心电图QT、QTc有所延长,但在正常范围内。以上结果与维拉帕米组相似。两组均无严重不良反应。结论:Dilacor治疗轻中度高血压安全而有效。

A Random, Single Blind, Parallel and Control Study in Treating Patients with Mild or Moderate Essential Hypertension with Diltiazem and Verapamil

Objective: To compare the effect and safety in treating mild or moderate essential hypertension with diltiazem (Dilacor) and verapamil. Methods: 49 patients with mild or moderate essential hypertension were selected and divided into two groups at random. Group A: 24 cases with verapamil 240mg everyday. Group B: 25 cases with Dilacor 180mg or 240mg everyday. Results: Blood pressure(BP) were contrasted effectively in 84% patients with Dilacor 180mg or 240mg after 8 weeks. Mean systolic BP decreased 9.92mmHg and mean diastolic BP decreased 10.48mmHg. QT and QTc of electrocardiogram were also prolonged, but in normal range. All the above results were similar with that of verapamil. There were no severe side effect in the two groups. Conclusion: Conclusion: Dilacor were effective and safety in treating patients with mild and moderate essential hypertension.